Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.
Fridrik MA, Jäger G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubauer M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W. Fridrik MA, et al. Among authors: schiller l. Eur J Cancer. 1998 Sep;34(10):1560-4. doi: 10.1016/s0959-8049(98)00140-3. Eur J Cancer. 1998. PMID: 9893628 Clinical Trial.
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Fridrik MA, Hausmaninger H, Linkesch W, Stöger M, Sill H, Neubauer M, Seewann HL, Klocker J, Haidinger R, Schiller L, Pont J, Raudaschl G, Falk M, Radaszkiewicz T. Fridrik MA, et al. Among authors: schiller l. J Clin Oncol. 1996 Jan;14(1):227-32. doi: 10.1200/JCO.1996.14.1.227. J Clin Oncol. 1996. PMID: 8558202 Clinical Trial.
Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.
Hausmaninger H, Lehnert M, Steger G, Sevelda P, Michlmayr G, Hehenwarter W, Fridrik M, Samonigg H, Schiller L, Manfreda D, et al. Hausmaninger H, et al. Among authors: schiller l. Onkologie. 1989 Oct;12(5):225-9. doi: 10.1159/000216651. Onkologie. 1989. PMID: 2685688 Clinical Trial.
[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].
Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S. Hilbe W, et al. Among authors: schiller l. Wien Klin Wochenschr. 2007;119(7-8):259-66. doi: 10.1007/s00508-007-0792-5. Wien Klin Wochenschr. 2007. PMID: 17492355 Review. German. No abstract available.
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.
Petru E, Andel J, Angleitner-Boubenizek L, Steger G, Bernhart M, Busch K, Gehmacher O, Hernler T, Kastner U, Lanz-Veit A, Pluschnigg U, Polachova J, Rohde M, Schiller L, Schramböck R, Stangl W, Thödtmann R, Zabernigg A. Petru E, et al. Among authors: schiller l. Wien Med Wochenschr. 2008;158(5-6):169-73. doi: 10.1007/s10354-008-0515-1. Wien Med Wochenschr. 2008. PMID: 18421559
Trust me: You can't trust everything that you read.
Schiller LR. Schiller LR. Proc (Bayl Univ Med Cent). 2024 Mar 7;37(3):465. doi: 10.1080/08998280.2024.2324654. eCollection 2024. Proc (Bayl Univ Med Cent). 2024. PMID: 38628333 Free PMC article. No abstract available.
165 results